SEARCH RESULTS

13 RESULTS

Lon S. Schneider on Aducanumab Decision Delayed for Three Months

COMMENT The three-month delay is a political win-win-win for the FDA, Biogen, and the indefatigable advocacy groups. The agency has had the necessary information to decide since November, but is either conflicted or carefully timing an announcement. Their current ...

Lon S. Schneider on Biogen/Eisai Halt Phase 3 Aducanumab Trials

COMMENT The outcomes of the aducanumab and crenezumab Phase 3 trials are disappointing but are as expected. Neither of the antibodies showed clinical efficacy evidence in their earlier phase trials. The previous, and regularly repeated, claims of efficacy from ...

Current Filters

  • TYPE: Comment x
  • Commentator: Schneider, Lon S. x

Remove all filters

Filter By

DATE RANGE
  • All
  • Past 7 Days
  • Past 30 Days
  • Past 90 Days
  • Past 12 Months
  • Specific Dates
    1. From
      To

TYPE